A
Afshin Dowlati
Researcher at University Hospitals of Cleveland
Publications - 320
Citations - 19042
Afshin Dowlati is an academic researcher from University Hospitals of Cleveland. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 47, co-authored 282 publications receiving 16109 citations. Previous affiliations of Afshin Dowlati include Case Western Reserve University.
Papers
More filters
Journal ArticleDOI
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan B. Sandler,Robert Gray,Michael C. Perry,Julie R. Brahmer,Joan H. Schiller,Afshin Dowlati,Rogerio Lilenbaum,David H. Johnson +7 more
TL;DR: The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths.
Journal ArticleDOI
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi,Julien Mazieres,David Planchard,Thomas E. Stinchcombe,Grace K. Dy,Scott J. Antonia,Leora Horn,Hervé Lena,Elisa Minenza,Bertrand Mennecier,Gregory A. Otterson,Luis T. Campos,David R. Gandara,Benjamin Levy,Suresh G. Nair Md,Gérard Zalcman,Jürgen Wolf,Pierre Jean Souquet,Editta Baldini,Federico Cappuzzo,Christos Chouaid,Afshin Dowlati,Rachel E. Sanborn,Ariel Lopez-Chavez,Christian Grohe,Rudolf M. Huber,Christopher T. Harbison,Christine Baudelet,Brian Lestini,Suresh S. Ramalingam +29 more
TL;DR: Nivolumab has clinically meaningful activity and a manageable safety profile in previously treated patients with advanced, refractory, squamous non-small cell lung cancer and these data support the assessment of nivolumsab in randomised, controlled, phase 3 studies of first-line and second-line treatment.
Journal ArticleDOI
Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data.
Nathan Levitan,Afshin Dowlati,Scot C. Remick,Hassan I. Tahsildar,Lynn D. Sivinski,Rebecca J. Beyth,Alfred A. Rimm +6 more
TL;DR: It is demonstrated that patients with concurrent DVT/PE and malignancy have a more than threefold higher risk of recurrent thromboembolic disease and death (from and cause) than patients with DVt/PE without malignancies.
Journal ArticleDOI
Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas
Howard A. Burris,Herbert Hurwitz,E. Claire Dees,Afshin Dowlati,Kimberly L. Blackwell,Bert H. O'Neil,Paul K. Marcom,Matthew J. Ellis,Beth Overmoyer,Suzanne F. Jones,Jennifer Harris,Deborah A. Smith,Kevin M. Koch,Andrew G. Stead,Steve Mangum,Neil L. Spector +15 more
TL;DR: Lapatinib was well tolerated at doses ranging from 500 to 1,600 mg once daily and clinical activity was observed in heavily pretreated patients with ErbB1-expressing and/or ErbbB2-overexpressing metastatic cancers, including four PRs in patients with trastuzumab-resistant breast cancers and prolonged stable disease in 10 patients.
Journal ArticleDOI
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.
Charles M. Rudin,John T. Poirier,Lauren Averett Byers,Caroline Dive,Afshin Dowlati,Julie George,John V. Heymach,Jane E. Johnson,Jonathan M. Lehman,David MacPherson,Pierre P. Massion,John D. Minna,Trudy G. Oliver,Vito Quaranta,Julien Sage,Roman K. Thomas,Christopher R. Vakoc,Adi F. Gazdar +17 more
TL;DR: This Opinion, written by many leading experts in small cell lung cancer (SCLC) research, proposes a new model of SCLC subtypes defined by differential expression of four key transcription regulators that should help to focus and accelerate therapeutic research.